BACKGROUND: We wanted to assess the efficacy and @entity137 of @entity1311 ( @entity1311 ) in previously untreated @entity1 with advanced @entity43 . No such study had been performed at the time of initiation of this study. @entity1 AND METHODS: The study population in this analysis consisted of 35 previously untreated @entity43 @entity1 , suboptimally resected at primary surgery. The initial @entity1311 dose was 175 mg/m2 given as a three-hour i.v. infusion every three weeks. RESULTS: A total of 225 @entity1311 courses were given to 35 @entity1 of whom 34 were evaluable for clinical response. Nine (26%) @entity1 obtained a complete response to @entity1311 , ten (29%) a partial response, seven (21%) stable disease and eight (24%) had progressive disease. Thus, the total response rate to @entity1311 treatment was 55% (19 of 34). The median duration of response for the 19 responding @entity1 was eight months (range 1-44.5+). The median duration for nine @entity1 with clinical complete response was 16 months (range 2-44.5+). A second-look laparotomy was performed in 15 @entity1 after six courses of @entity1311 . Of these, five obtained a histopathologically complete remission, five a partial remission and five stable disease. The five @entity1 with pathologically complete remissions are alive with a median progressive-free survival of 24.5 months (range 15(+)-44.5+). The median progression-free survival for all @entity1 was 6.1 months (range 1-44.5+). @entity137 consisted mainly of @entity1398 , easily controlled. Other @entity137 were @entity925 / @entity4841 and @entity1897 . Three @entity1 experienced a severe anaphylactic reaction during the first course. CONCLUSION: This study showed that @entity1311 is an effective and safe drug for first-line treatment of @entity43 .

XXXX in untreated FIGO stage III suboptimally resected @entity43 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'stage III ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Taxol'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgia'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgia']
@entity1311 :: (MESH:D017239,Chemical) :: ['Paclitaxel']
